Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.74 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.73 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195795 | 1.00 | DPP4 (0.74) | DPP4DPP8DPP7DPP9 | |
| Phosphoric Acid SCHEMBL29041092 | 0.96 | DPP4 (0.68) | DPP4DPP8DPP7DPP9 | |
| Phosphoric Acid SCHEMBL30040047 | 0.96 | DPP4 (0.68) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL28706530 | 0.87 | DPP4 (0.56) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL29040979 | 0.85 | DPP4 (0.55) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL29040977 | 0.85 | DPP4 (0.55) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL28698252 | 0.85 | DPP4 (0.55) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL5491159 | 0.85 | DPP4 (1.00) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL28710941 | 0.82 | DPP4 (0.51) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL28711236 | 0.82 | DPP4 (0.51) | DPP4DPP8DPP7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057751-B | Preparation method of DPP-IV inhibitor and key intermediate thereof | 盛世泰科生物医药技术(苏州)有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114057751-A | Preparation method of DPP-IV inhibitor and key intermediate thereof | 盛世泰科生物医药技术(苏州)有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11046701-B2 | Salt of cetagliptin, preparation method thereof, pharmaceutical composition, and use thereof | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3785713-A1 | SALT OF CETAGLIPTIN, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CGenetech (Suzhou, China) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200123164-A1 | SALT OF CETAGLIPTIN, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046701-B2 | Salt of cetagliptin, preparation method thereof, pharmaceutical composition, and use thereof | DPP4, SLC5A1, ALPI | DPP4 1/4885DPP8 8/4885DPP7 4/4885 |
| US-20200123164-A1 | SALT OF CETAGLIPTIN, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | DPP4, SLC5A1, ALPI | DPP4 1/4885DPP8 8/4885DPP7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.